Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

被引：44
|
作者：
Ciurea, Stefan O. [1 ]
Sadegi, Barry [2 ]
Wilbur, Andrew [2 ]
Alagiozian-Angelova, Victoria [3 ]
Gaitonde, Sujata [3 ]
Dobogai, Lisa C. [1 ]
Akard, Luke P. [4 ]
Hoffman, Ronald [5 ]
Rondelli, Damiano [1 ]
机构：
[1] Univ Illinois, Hematol Oncol Sect, Coll Med, Div Hematol,Dept Med, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Med, Dept Radiol, Chicago, IL 60612 USA
[3] Univ Illinois, Coll Med, Div Hematopathol, Dept Pathol, Chicago, IL 60612 USA
[4] Indiana Blood & Marrow Transplantat Program, Indianapolis, IN USA
[5] Mt Sinai Sch Med, Hematol Oncol Sect, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷 / 01期
关键词：
myeloproliferative disorder; splenomegaly; reduced-intensity conditioning stem cell transplantation; myelofibrosis;
D O I：
10.1111/j.1365-2141.2008.07010.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Changes in spleen size postallogeneic haematopoietic stem cell transplantation (HSCT) in patients with primary myelofibrosis have been poorly characterized. We analysed 10 patients with myelofibrosis and splenomegaly following a reduced-intensity allogeneic HSCT. All patients fully engrafted donor cells including five patients with extensive splenomegaly. Extensive splenomegaly was associated with a prolonged time to neutrophil and platelet recovery. In all 10 patients, a progressive reduction of splenomegaly was documented within 12 months post-transplant and paralleled the reduction of marrow fibrosis. These findings suggest that myelofibrosis patients with extensive splenomegaly may proceed with allogeneic HSCT without prior splenectomy.
引用
收藏
页码：80 / 83
页数：4
相关论文
共 50 条
  • [31] Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis
    Palmer, Jeanne
    Jain, Tania
    Kunze, Katie L.
    Partain, Daniel K.
    Khera, Nandita
    Sproat, Lisa
    Noel, Pierre
    Slack, James L.
    Roy, Vivek
    Leis, Jose F.
    Hogan, William J.
    Tefferi, Ayalew
    Fauble, Veena D. S.
    Patnaik, Mrinal M.
    Kosiorek, Heidi Elizabeth
    Mesa, Ruben A.
    BLOOD, 2017, 130
  • [32] Hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation and antithymocyte globulin treatment
    Ecsedi, M.
    Schmohl, J.
    Zeiser, R.
    Drexler, B.
    Halter, J.
    Medinger, M.
    Duyster, J.
    Kanz, L.
    Passweg, J.
    Finke, J.
    Bethge, W.
    Lengerke, C.
    Oncology Research and Treatment, 2015, 38 : 262 - 262
  • [33] Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Rampal, Raajit K.
    Tamari, Roni
    Zhang, Nan
    McNamara, Caroline Jane
    Rapaport, Franck
    Litvin, Rivka
    Maloy, Molly A.
    Castro-Malaspina, Hugo
    Giralt, Sergio
    Weinberg, Rona Singer
    Mascarenhas, John
    Mesa, Ruben A.
    Rondelli, Damiano
    Dueck, Amylou C.
    Levine, Ross L.
    Gupta, Vikas
    Hoffman, Ronald
    BLOOD, 2016, 128 (22)
  • [34] Decreased relapse risk after allogeneic hematopoietic stem cell transplantation (HSCT) in myelofibrosis with splenomegaly
    Ditschkowski, M.
    Steckel, N. K.
    Trenschel, R.
    Gromke, T.
    Beelen, D. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 229 - 230
  • [35] MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
    Rondelli, Damiano
    Goldberg, Judith D.
    Isola, Luis
    Price, Leah S.
    Shore, Tsiporah B.
    Boyer, Michael
    Bacigalupo, Andrea
    Rambaldi, Alessandro
    Scarano, Marco
    Klisovic, Rebecca B.
    Gupta, Vikas
    Andreasson, Bjorn
    Mascarenhas, John
    Wetzler, Meir
    Vannucchi, Alessandro M.
    Prchal, Josef T.
    Najfeld, Vesna
    Orazi, Attilio
    Weinberg, Rona S.
    Miller, Crystal
    Barosi, Giovanni
    Silverman, Lewis R.
    Prosperini, Giuseppe
    Marchioli, Roberto
    Hoffman, Ronald
    BLOOD, 2014, 124 (07) : 1183 - 1191
  • [36] REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Kuzmina, Larisa A.
    Parovichnikova, Elena N.
    Sorokina, Tamara V.
    Petinati, Natalia A.
    Drokov, Michail Y.
    Savchenko, Valeriy G.
    ANNALS OF HEMATOLOGY, 2013, 92 : S18 - S19
  • [37] Reduced intensity conditioning for allogeneic stem cell transplantation in patients with multiple myeloma
    Vaz, CP
    Campilho, F
    Campos, A
    Guerra, M
    Mendez, JC
    Soares, M
    Martinho, A
    Barbosa, IL
    Roncon, S
    Carvalhais, A
    Pimentel, P
    BONE MARROW TRANSPLANTATION, 2003, 31 : S159 - S159
  • [38] Reduced-intensity allogeneic stem cell transplantation in patients with myelodysplastic syndrome
    Terriou, L.
    Esperou, H.
    Milpied, N.
    Boiron, M.
    Vernant, P.
    Gratecos, N.
    Michallet, M.
    Jouet, J. P.
    Yakoub-Agha, I.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S205 - S206
  • [39] Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis
    Snyder, David S.
    Palmer, Joycelynne
    Stein, Anthony S.
    Pallarkat, Vinod
    Sahebi, Firoozeh
    Cohen, Sandra
    Vora, Nayana
    Gaal, Karl
    Nakamura, Ryo
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (11) : 1161 - 1168
  • [40] Impact of molecular genetics on outcome after different conditioning intensity in myelofibrosis undergoing allogeneic stem cell transplantation
    Gagelmann, Nico
    Ditschkowski, Markus
    Bogdanov, Rashit
    Bredin, Swan
    Robin, Marie
    Cassinat, Bruno
    Shahswar, Rabia
    Thol, Felicitas
    Heuser, Michael
    Beelen, Dietrich
    Badbaran, Anita
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2019, 54 : 56 - 57
12345